Compass Therapeutics, Inc. financial data

Symbol
CMPX on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1167% % -51%
Debt-to-equity 15% % 173%
Return On Equity -49% % -51%
Return On Assets -42% % -38%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 177,862,102 shares 29%
Common Stock, Shares, Outstanding 177,572,000 shares 29%
Entity Public Float $98,000,000 USD -65%
Common Stock, Value, Issued $53,000 USD 279%
Weighted Average Number of Shares Outstanding, Basic 168,782,000 shares 23%
Weighted Average Number of Shares Outstanding, Diluted 137,600,000 shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $55,329,000 USD 49%
General and Administrative Expense $16,091,000 USD 11%
Operating Income (Loss) $71,420,000 USD -29%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $16,633,000 USD -54%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $65,804,000 USD -38%
Earnings Per Share, Basic 0 USD/shares -22%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $46,212,000 USD 138%
Marketable Securities, Current $173,683,000 USD 76%
Assets, Current $221,120,000 USD 57%
Property, Plant and Equipment, Net $119,000 USD -76%
Operating Lease, Right-of-Use Asset $9,452,000 USD 36%
Other Assets, Noncurrent $568,000 USD 78%
Assets $231,259,000 USD 55%
Accounts Payable, Current $3,095,000 USD 222%
Accrued Liabilities, Current $8,684,000 USD 198%
Liabilities, Current $12,412,000 USD 180%
Operating Lease, Liability, Noncurrent $9,234,000 USD 46%
Liabilities $21,646,000 USD 101%
Accumulated Other Comprehensive Income (Loss), Net of Tax $274,000 USD -44%
Retained Earnings (Accumulated Deficit) $415,456,000 USD -19%
Stockholders' Equity Attributable to Parent $209,613,000 USD 51%
Liabilities and Equity $231,259,000 USD 55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,208,000 USD 4.9%
Net Cash Provided by (Used in) Financing Activities $815,000 USD -105%
Net Cash Provided by (Used in) Investing Activities $11,588,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 177,572,000 shares 29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,435,000 USD -340%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46,780,000 USD 141%
Deferred Tax Assets, Gross $61,417,000 USD 39%
Operating Lease, Liability $9,867,000 USD 43%
Depreciation $100,000 USD -50%
Payments to Acquire Property, Plant, and Equipment $18,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $66,016,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid $11,813,000 USD 38%
Property, Plant and Equipment, Gross $6,739,000 USD -6.5%
Operating Lease, Liability, Current $633,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,204,000 USD 117%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,588,000 USD 117%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,946,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,249,000 USD 59%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,294,000 USD 59%
Operating Lease, Payments $1,300,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $1,896,000 USD 291%
Share-based Payment Arrangement, Expense $8,781,000 USD 11%